Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
Jorge J Castillo, Edward N Libby, Stephen M Ansell, M Lia Palomba, Kirsten Meid, Catherine A Flynn, Carly Leventoff, Christopher B Hergott, Tomasz Sewastianik, Elizabeth A Morgan, Ruben Carrasco, Jonathan R Fromm, Guang Yang, Zachary Hunter, Steven P Treon
Abstract
Daratumumab was associated with an overall response of 23% and a median PFS of 2 months in previously treated patients with WM. The 2 patients who attained a partial response to daratumumab exhibited higher baseline CD38 median fluorescent intensity in plasma cells.
Topics & Concepts
DaratumumabMacroglobulinemiaWaldenstrom macroglobulinemiaMedicineInternal medicineOncologyMulticenter studyMultiple myelomaBortezomibLymphomaRandomized controlled trialChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders